Page last updated: 2024-12-07

lupinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lupinine is an alkaloid found in various plant species, including lupine (Lupinus spp.). It is a bicyclic quinolizidine alkaloid with a characteristic structure that includes a six-membered ring fused to a five-membered ring. The synthesis of lupinine is a complex process that involves various steps, including cyclization and reduction reactions. Lupinine has shown various pharmacological effects, such as anti-inflammatory, antioxidant, and anticancer activities. These effects have led to research investigating its potential as a therapeutic agent. Studies have shown that lupinine can interact with specific receptors and enzymes in the body, contributing to its observed effects. The compound's importance lies in its potential as a source of bioactive molecules with therapeutic applications. Research continues to explore the mechanisms of action, structure-activity relationships, and potential applications of lupinine and its derivatives. '

lupinine: RN given refers to parent cpd(1R-trans)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91461
CHEMBL ID459397
CHEBI ID28012
SCHEMBL ID177708
MeSH IDM0065650

Synonyms (72)

Synonym
CHEBI:28012 ,
1s-cis-octahydro-2h-quinolizine-1-methanol
(1r,9ar)-octahydro-2h-quinolizin-1-ylmethanol
nsc21723
2h-quinolizine-1-methanol, (1r-trans)-
nsc-21723
(-)-lupinine
DIVK1C_006702
SDCCGMLS-0066745.P001
einecs 207-638-0
brn 0080447
nsc 21723
octahydroquinolizine-1-methanol
(1r-trans)-octahydro-2h-quinolizine-1-methanol
SPECTRUM_001736
SPECTRUM4_001921
SPECTRUM5_000773
BSPBIO_002768
lupinine
486-70-4
KBIO2_004784
KBIO2_007352
KBIO3_001988
KBIO2_002216
KBIOGR_002262
KBIOSS_002216
KBIO1_001646
SPECTRUM3_001094
SPECPLUS_000606
SPECTRUM2_000499
SPBIO_000397
SPECTRUM1504021
STK050782
CHEMBL459397
HMS1922N13
[(1r,9ar)-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-yl]methanol
AKOS004120072
((1r,9ar)-octahydro-1h-quinolizin-1-yl)methanol
33baj73u1f ,
5-21-01-00338 (beilstein handbook reference)
unii-33baj73u1f
CCG-38712
((1r,2r)-6-azabicyclo[4.4.0]dec-2-yl)methan-1-ol
(1r,9ar)-1-(octahydroquinolizin-1-yl)methanol
(1r,9ar)-1-(octahydro-quinolizin-1-yl)-methanol
HDVAWXXJVMJBAR-VHSXEESVSA-N
2h-quinolizine-1-methanol, octahydro-, (1r-trans)-(+/-)-
(+/-)-lupinine
f74rac8a5q ,
unii-f74rac8a5q
lupinine dl-form [mi]
2h-quinolizine-1-methanol, octahydro-, (1r,9ar)-rel-
lupinine, (+/-)-
SCHEMBL177708
(1r,9ar)-octahydro-2h-quinolizine-1-methanol
lupinine [mi]
l-lupinine
J-500379
J-500002
mfcd00213431
(-)-lupinine, aldrichcpr
DTXSID00197565
A871891
Q412589
(trans-octahydro-1h-quinolizin-1-yl)methanol
BRD-K45978015-001-03-6
BS-35956
((1r,9ar)-octahydro-2h-quinolizin-1-yl)methanol
(1r,9ar)-octahydro-2h-quinolizin-1-ylmethanol(saltdata: free)
CS-0081248
HY-121219
F77309

Research Excerpts

Overview

Lupinine is an elementary representative of a large quinolizidine alkaloid group.

ExcerptReferenceRelevance
"Lupinine is an elementary representative of a large quinolizidine alkaloid group. "( Synthesis, Structure and Biological Activity of (1
Fazylov, SD; Muldakhmetov, ZM; Nurkenov, OA; Nurmaganbetov, ZS; Seidakhmetova, RB; Shulgau, ZT, 2022
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolizidine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1503774Cytotoxicity against human HL cells assessed as cell viability at 50 uM after 72 hrs by resazurin dye based fluorescence assay relative to control2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID337604Displacement of [3H]nicotin from nicotinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID337605Displacement of [3H]quinuclidinyl benzilate from muscarinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1503775Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells assessed as chlamydial inhibition at 50 uM after 70 hrs by fluorescent microscopic analysis2017Journal of natural products, 10-27, Volume: 80, Issue:10
Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (18.18)18.7374
1990's1 (3.03)18.2507
2000's9 (27.27)29.6817
2010's15 (45.45)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.68 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]